Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer Muhammad Wasif SaifShahrukh Hashmi Review 12 September 2007 Pages: 349 - 354
A novel N-alkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type Amit A. DeorukhkarRamesh ChanderKrishna B. Sainis Original Article 12 April 2007 Pages: 355 - 363
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL Amrita V. KamathJian WangPunit H. Marathe Original Article 11 April 2007 Pages: 365 - 376
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies Andrew EvansVictoria BatesRachel Airley Original Article 23 May 2007 Pages: 377 - 393
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging C. BornmannR. GraeserE. von Dobschuetz Original Article 07 June 2007 Pages: 395 - 405
Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones Christopher M. SturgeonBruno CinelMichel Roberge Original Article 18 April 2007 Pages: 407 - 413
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer Bernard RoyerDelphine DelroeuxXavier Pivot Original Article 15 May 2007 Pages: 415 - 421
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors Antonio JimenoMichelle A. RudekRoss C. Donehower Original Article 12 April 2007 Pages: 423 - 433
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma Robert J. JonesRobert E. HawkinsT. R. Jeffry Evans Original Article 18 April 2007 Pages: 435 - 441
Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells Fabio FusiAntonella FerraraSimona Saponara Original Article 27 April 2007 Pages: 443 - 451
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer Ramesh K. RamanathanJoel PicusAllen Cohn Original Article 22 May 2007 Pages: 453 - 458
Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance Shuai ChenMingjun ZhangLong Yu Original Article 23 May 2007 Pages: 459 - 469
Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line Kenshi SakayamaNaohiko MashimaHiroshi Masuno Original Article 05 June 2007 Pages: 471 - 479
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene Ricardo BellottValérie Le MorvanJacques Robert Original Article 05 May 2007 Pages: 481 - 488
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors Noboru YamamotoAtsushi HoriikeTomohide Tamura Original Article 05 May 2007 Pages: 489 - 496
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide Francisco ChungJenny LiuBruce C. Baguley Original Article 01 May 2007 Pages: 497 - 502
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer Fumiyoshi OhyanagiAtsushi HoriikeMakoto Nishio Original Article 05 May 2007 Pages: 503 - 508
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial Daigo YamamotoSatoru IwaseYoshinori Nagumo Original Article 22 May 2007 Pages: 509 - 514
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period Carolyn D. BrittenFairooz KabbinavarDennis Slamon Original Article 16 May 2007 Pages: 515 - 524
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells Jiannong LiJean VialletEric B. Haura Original Article 16 May 2007 Pages: 525 - 534